{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:45:30Z","timestamp":1769553930032,"version":"3.49.0"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,1,31]],"date-time":"2008-01-31T00:00:00Z","timestamp":1201737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:title><jats:sc>Summary<\/jats:sc><\/jats:title><jats:p><jats:bold><jats:styled-content>Objective:<\/jats:styled-content>Eyelid myoclonia with absences (EMA) or Jeavons syndrome characterized by eyelid myoclonia (EM) (with or without absences), eye closure\u2010induced EEG paroxysms, and photosensitivity. We conducted an open\u2010label trial of levetiracetam in EMA.<\/jats:bold><\/jats:p><jats:p><jats:bold><jats:styled-content>Patients and Methods<\/jats:styled-content>: Patients were recruited in different Italian Epilepsy Centres. Levetiracetam was administrated at starting dose of 10 mg\/kg\/day up to 50\u201360 mg\/kg\/day in two doses. Treatment period included a 5\u20136 week up\u2010titration phase and a 12\u2010week evaluation phase. The number of days with EM (i.e., days with seizures, DwS) and number of generalized tonic\u2013clonic seizures (GTCS) were evaluated. Analysis of intent\u2010to\u2010treat population was performed using Fisher's and Wilcoxon tests.<\/jats:bold><\/jats:p><jats:p><jats:bold><jats:styled-content>Results<\/jats:styled-content>: Thirty\u2010five patients (23 F) with a mean age of 19 \u00b1 6 years were recruited. Twenty\u2010seven had previously undergone one to five adequate trials of antiepileptic drugs. The median number of DwS\/month was 12 \u00b1 8.2. Twenty\u2010one patients experienced GTCS (median number\/month: 1 \u00b1 0.2). Thirty\u2010four subjects completed the trial. Levetiracetam was well tolerated (mean dose: 1985 mg\/day). Responders were 28\/35 (80%) patients, nine taking levetiracetam as monotherapy. Six patients were seizure\u2010free, 15 had \u226575% and seven &gt;50% seizure reduction. GTCS remitted in 14 out of 21 (66.6%) patients. The number\/month of DwS (median: 12 vs 5; p = 0.0001) and of GTCS (median: 1 vs 0; p = 0.0001) decreased compared to baseline period. Disappearance or clear reduction in paroxysmal abnormalities at eye closure occurred in 20 of the responders and photoparoxysmal response in 19. Mean follow\u2010up was 23.9 \u00b1 18.5 months.<\/jats:bold><\/jats:p><jats:p><jats:bold><jats:styled-content>Conclusion<\/jats:styled-content>: Levetiracetam is effective and well tolerated in EMA. Placebo\u2010controlled studies should confirm these findings.<\/jats:bold><\/jats:p>","DOI":"10.1111\/j.1528-1167.2007.01524.x","type":"journal-article","created":{"date-parts":[[2008,1,31]],"date-time":"2008-01-31T11:21:42Z","timestamp":1201778502000},"page":"425-430","source":"Crossref","is-referenced-by-count":66,"title":["A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome)"],"prefix":"10.1111","volume":"49","author":[{"given":"Pasquale","family":"Striano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Sofia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Capovilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Rubboli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Di Bonaventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonietta","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Fontanillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Teresa","family":"Giallonardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Viri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Zara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Striano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,1,31]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.56.12.1312"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000268699.34614.d3"},{"key":"e_1_2_6_4_1","article-title":"Study proposal of electroclinical features in eyelid myoclonia with absences (EMA)","author":"Capovilla G","year":"2006","journal-title":"Italian League Against Epilepsy (LICE)"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000110193.78872.DD"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2006.02.006"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1684\/j.1950-6945.2005.tb00127.x","article-title":"Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes","volume":"7","author":"Di Bonaventura C","year":"2005","journal-title":"Epileptic Disord"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.10401.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.39503.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2003.02141.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb00509.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000217916.00225.3a"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-001-0881-9"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.1977.tb08014.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(96)00031-9"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0987-7053(99)90045-X"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308208101"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.56902.x"},{"key":"e_1_2_6_19_1","first-page":"17","volume-title":"Eyelid myoclonia with absences","author":"Panayiotopoulos CP","year":"1996"},{"key":"e_1_2_6_20_1","first-page":"17","volume-title":"Eyelid myoclonia with absences","author":"Richens A","year":"1996"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2006.09.004"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.05.013"},{"key":"e_1_2_6_23_1","first-page":"443","article-title":"Epileptic seizures on closing the eyes and upon the sudden disappearance of light","volume":"34","author":"Striano S","year":"1979","journal-title":"Acta Neurol (Naples)"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0987-7053(02)00343-X"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20530"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000265222.24102.db"},{"key":"e_1_2_6_27_1","unstructured":"UCB\/N166 study.Levetiracetam as Add\u2010on Treatment of Myoclonic Jerks in Adolescents + Adults. Available at ClinicalTrials.gov (http:\/\/clinicaltrials.gov\/show\/NCT00150774)."}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2007.01524.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2007.01524.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T13:49:34Z","timestamp":1737899374000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2007.01524.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,31]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1111\/j.1528-1167.2007.01524.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2007.01524.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,31]]}}}